CD20L (MS4A3), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD20L (MS4A3), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD20L (MS4A3), Human |
| Clone | REA756 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | PE-Vio 770 conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Intracellular flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD20L (MS4A3) Antibody, anti-human, PE-Vio® 770, REAfinity™. Clone REA756 recognizes the human CD20L, an intracytoplasmic membrane protein, which is also known as Htm4 or MS4A3. It is present specifically in hematopoietic cells and tissues. CD20L functions as a hematopoietic modulator for the G1-S cell cycle transition. It binds to cyclin-dependent kinase inhibitor 3 (CDKN3/KAP) and modulates the level of phosphorylation of cyclin-dependent kinase 2 (CDK2). | Additional information: Clone REA756 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | CD20L, HTM4 |
| Gene, Accession # | Gene ID: 932 |
| Catalog # | 130-110-856 |
| Price | $162 |
| Order / More Info | CD20L (MS4A3), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Donato, J. L. et al. (2002) Human HTm4 is a hematopoietic cell cycle regulator. J. Clin. Invest. 109 (1): 51-58. | Chinami, M. et al. (2005) Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of Cdk2. J. Biol. Chem. 280 (17): 17235-17242. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies